linjc16/ctgov huggingface dataset:
An Internet-Based Smokeless Tobacco Cessation Program for Teens

Study Overview
=================
Brief Summary
-----------------
To compare the efficacy of a targeted, tailored, and highly interactive smokeless tobacco cessation website to a website with more static information that is similar to websites that can be found through a typical Internet search.

Official Title
-----------------
QuitSpit: An Internet-Based Smokeless Tobacco Cessation Program for Teens

Conditions
-----------------
Smokeless Tobacco Use

Intervention / Treatment
-----------------
* Behavioral: Tailored, enhanced condition
* Behavioral: Usual Care


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 14-25 years of age Have access to the Internet Currently using smokeless tobacco products Currently contemplating quitting all tobacco products Able to read and write English; and Willing to share phone number, e-mail, and mailing address with the research project

Ages Eligible for Study
-----------------
Minimum Age: 14 Years
Maximum Age: 25 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Usual Care<br> | Behavioral: Usual Care<br>* The Usual Care condition will provide access to typical smokeless tobacco cessation information and links to commonly available Web-based smokeless tobacco cessation resources.<br>|
| Experimental: Enhanced<br> | Behavioral: Tailored, enhanced condition<br>* Intervention will provide a personalized, interactive tobacco cessation Web application, based on existing empirically validated smokeless tobacco cessation programs.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Abstinence from all tobacco |  | 3 months and 6 months | 
| Abstinence from smokeless tobacco |  | 3 months and 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evaluate the relative effectiveness of the two programs on secondary outcomes, including reduction in smokeless tobacco use, number of quit attempts, and confidence in quitting. |  | 3 months and 6 months | 
| Identify participant characteristics, including demographic characteristics, initial smokeless tobacco use and dependence, and patterns of program use that predict treatment outcomes. |  | 3 months and 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Smokeless tobacco
Lung Tissue Research Consortium

Study Overview
=================
Brief Summary
-----------------
The LTRC will facilitate histopathological research of pulmonary diseases by collecting lung tissues from donors and preparing and distributing collections of tissue specimens to researchers within and outside the LTRC. Collections of specimens will be linked to individual clinical data appropriate to the particular disease. The primary goal of the LTRC is to identify participants with suspected lung cancer or metastatic disease who are willing to provide informed consent for research use of their specimens and data. Secondarily, the LTRC investigators intend to collect clinical data, limited exposure data, physiologic studies, and radiographic studies from these participants.

Official Title
-----------------
Lung Tissue Research Consortium

Conditions
-----------------
Chronic Obstructive Pulmonary Disease, Interstitial Lung Disease

Intervention / Treatment
-----------------
* Procedure: Lung biopsy/lobectomy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adults ages 21 or older who are undergoing lung surgery for suspected malignancy or metastases. Exclusion Criteria: Diagnosis of cystic fibrosis or pulmonary hypertension. Any other condition that, in the judgment of the investigator, precludes participation. Failure to obtain written consent.

Ages Eligible for Study
-----------------
Minimum Age: 21 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Lung biopsy/lobectomy<br>Adults ages 21 or older who are undergoing lung surgery for suspected malignancy or metastases. | Procedure: Lung biopsy/lobectomy<br>* Lung biopsies and lobectomies are not experimental. Participants will undergo a lung biopsy or a lobectomy as part of standard of care.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Clinical diagnosis | A final diagnosis of the participant's lung disease will be rendered by the clinical center PI. | Two months following surgery |
The Role of Platelet Rich Plasma for Erectile Dysfunction

Study Overview
=================
Brief Summary
-----------------
Purpose of Study: This randomized controlled trial investigates the role that platelet rich plasma injections into the penis may play to improve erectile function in men with erectile dysfunction.

Detailed Description
-----------------
Eligibility: Men with erectile dysfunction. Ages 50-80. International Index of Erectile Function score of mild (17-21/25) or moderate (8-16/25). Intervention and Evaluation:Men who consent to join the trial will be randomized to receive either a single injection PRP or saline to the penis. All patients will have blood drawn in clinic the day of injection. Those randomized to PRP arm will have their own blood prepared and separated into the PRP. This solution of their own blood will be injected back into the penis. Follow Up: Men will be evaluated at 1 , 3, and 6 months after the injections and then asked to complete the IIEF by phone or by electronic means

Official Title
-----------------
The Role of Platelet Rich Plasma for Erectile Dysfunction

Conditions
-----------------
Erectile Dysfunction

Intervention / Treatment
-----------------
* Biological: Platelet rich plasma
* Other: Placebo Sham Injection


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: history of mild to moderate erectile dysfunction measured by IIEF Exclusion Criteria: history or prostate cancer treatment (prostatectomy, radiation, brachytherapy)

Ages Eligible for Study
-----------------
Minimum Age: 50 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Interventional Model Description: Randomized Controlled Trial
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Sham Comparator: Placebo<br>All arms will have phlebotomy (blood drawn). This group will receive saline injection only. | Other: Placebo Sham Injection<br>* sham injection<br>* Other names: Placebo;|
| Experimental: Platelet rich plasma<br>All arms will have phlebotomy (blood drawn). This group will receive PRP injection only. | Biological: Platelet rich plasma<br>* PRP will be used in the experimental arm.<br>* Other names: blood plasma;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Erectile Function Change | The rate of change in erectile function measured by IIEF | at 1, 3 and 6 months |
Motivation and Nicotine Patch Treatment for Under-served Smokers

Study Overview
=================
Brief Summary
-----------------
The goal of this study is to test, in combination with the nicotine patch, the incremental efficacy of a motivationally tailored behavioral intervention over a minimal intervention. The interventions will be delivered through primary care medical clinics. The defined population comprises low income, less educated smokers who will vary in their level of motivation to quit smoking. Patients will be randomly assigned within clinics to one of two interventions (a) Nicotine patch prescription plus brief physician advice (minimal care); and (b) Nicotine patch prescription plus brief physician advice, with the addition of a tailored motivational intervention, a behavioral skills counseling session for smoking cessation.

Official Title
-----------------
Motivation and Nicotine Patch Treatment for Under-served Smokers

Conditions
-----------------
Smoking Cessation

Intervention / Treatment
-----------------
* Behavioral: Brief physician advice
* Drug: nicotine patch
* Behavioral: Individually Tailored Behavioral Skills training


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18 years of age or older Currently smoking at least 10 cigarettes/day for past 3 months Speak English or Spanish Have a telephone or live close to a relative or neighbor with a telephone Agree to participate in the study and be available over the next 6 months. Exclusion Criteria: Unable to use nicotine patch due to medical status Active skin condition or history of skin allergy Currently using smokeless tobacco, nicotine replacement or other smoking cessation treatment Pregnant or nursing

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Parallel Assignment


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Minimal<br>Brief physician advice to quit smoking plus nicotine patch | Behavioral: Brief physician advice<br>* Brief physician advice to quit smoking<br>Drug: nicotine patch<br>* nicotine patch<br>|
| Experimental: Tailored<br> | Behavioral: Brief physician advice<br>* Brief physician advice to quit smoking<br>Drug: nicotine patch<br>* nicotine patch<br>Behavioral: Individually Tailored Behavioral Skills training<br>* Individually tailored behavioral skills training for smoking cessation<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Effectiveness of WB-EMS Versus HIT-Resistance Training (RT)

Study Overview
=================
Brief Summary
-----------------
The main aim of the study is to determine the effects of Whole-Body Electromyostimulation (WB-EMS) on body composition and muscle strength compared with the golden standard High Intensity Resistance Exercise Training (HIT) in healthy sedentary middle aged males.

Official Title
-----------------
Comparison of the Effect of Whole-Body Electromyostimulation Versus High Intensity Resistance Exercise Training on Body Composition and Strength in Middle Aged Males

Conditions
-----------------
Healthy, Sedentary, Untrained

Intervention / Treatment
-----------------
* Other: Whole Body Electromyostimulation
* Other: High Intensity Resistance Exercise Training


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: male, 25 to 55 years old sedentary / untrained Body Mass Index 20 - 30 kg/m2 Exclusion Criteria: absent ≥ 2 weeks during the interventional period medication or diseases with relevant impact on muscle metabolism conditions that prevent WB-EMS (e.g. epilepsy, cardiac pacemaker) severe neurological diseases

Ages Eligible for Study
-----------------
Minimum Age: 25 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Whole Body Electromyostimulation<br> | Other: Whole Body Electromyostimulation<br>* Supervised WB-EMS, 3 sessions in 2 weeks (1,5 sessions/week) for 14 weeks<br>|
| Experimental: High Intensity Resistance Exercise Training<br>Supervised High Intensity Resistance Exercise 2-3 session/week/14 weeks | Other: High Intensity Resistance Exercise Training<br>* Supervised High Intensity Resistance Exercise Training (HIT) 2-3 sessions/week for 14 weeks<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Lean Body mass | Lean Body Mass as assessed by Dual Energy x-Ray Absorptiometry (DXA) was determined twice, at baseline and after 14 weeks of exercise (WB-EMS or HIT) | 14 weeks (baseline to 14 week follow-up assessment) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Appendicular Skeletal Muscle Mass | Appendicular Skeletal Muscle Mass (ASMM) as assessed by DXA was determined at baseline and after 14 weeks of exercise (WB-EMS or HIT) | 14 weeks (baseline to 14 week follow-up assessment) | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Whole-Body-Electromyostimulation, High Intensity Resistance Exercise Training (HIT), Lean Body Mass, Muscle Strength
DYsphagiA in interMedIate Care UnitS

Study Overview
=================
Brief Summary
-----------------
Retrospective study in intermediate care unit patients on the incidence, Risk factors, and effects on mortality of dysphagia. During a 6-month observational period, routine data will be collected and analysed.

Official Title
-----------------
DYsphagiA in interMedIate Care UnitS - a Retrospective Analysis of Available Data

Conditions
-----------------
Dysphagia

Intervention / Treatment
-----------------
* Other: Screening for dysphagia along clinical routine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Intermediate care unit patients admitted within the observational period Exclusion Criteria: documented refusal to General Consent
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Dysphagia screening positive<br> | Other: Screening for dysphagia along clinical routine<br>* Screening for dysphagia using the water swallow test in intermediate care unit patients<br>|
| Dysphagia screening negative<br> | Other: Screening for dysphagia along clinical routine<br>* Screening for dysphagia using the water swallow test in intermediate care unit patients<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of positive screening (first screening) for dysphagia in neurosurgical intermediate care unit patients | incidence: percentage of patients with screening positivity at first screening | within 8 hours from intermediate care unit admission |
Efficacy Study for Treatment of Dementia in Progressive Supranuclear Palsy

Study Overview
=================
Brief Summary
-----------------
to show that patients improve and stabilize after 12 -24 week treatment with rivastigmine in memory function use of rivastigmine has a positive effect on apathy in PSP patients therapy with rivastigmine has a no positive benefit on speech and overall results of the MMST changes in motor activity are associated with changes in language and overall results of the in MMST

Official Title
-----------------
Rivastigmine (Exelon®) for Treatment of Dementia in Patient With Progressive Supranuclear Paresis Open Label Phase 2 Study

Conditions
-----------------
Progressive Supranuclear Palsy, Dementia

Intervention / Treatment
-----------------
* Drug: rivastigmine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: diagnosis of PSP willingness to participate in the study informed consent ability to speak no further CNS diseases written informed consent stable state of health ability to give informed consent, will checked by an independent physician Exclusion Criteria: alcohol abuses acute psychosis pregnancy or lactation known previous drug reaction or hypersensitivity of rivastigmine or other carbamate derivatives liver failure known sick sinus syndrome or excitation disturbance known ulcus ventriculi or duodenal ulcer known asthma or COPD seizures renal failure

Ages Eligible for Study
-----------------
Minimum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: 1<br>patients take 6 mg rivastigmine daily, if well tolerable increase to 12 mg rivastigmine maximum daily | Drug: rivastigmine<br>* rivastigmine 6 mg up to 12 mg daily; Taken in two doses from 3 mg to 6 mg Rivastigmine twice a day<br>* Other names: Exelon;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| improvement in neuropsychological assessments for memory and executive function, e.g. tested by Tower of London Test, CERAD Battery and Logical Memory Test (WMSR) |  | 6 month | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| changes in speech function and improvement of quality of life |  | 6 Month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
PSP, dementia, neuropsychology, treatment
Sickle Cell Anemia Screening and Prevention in Northern Israel

Study Overview
=================
Brief Summary
-----------------
Since 1987, a screening for β Thalassemia in pregnant women is carried on in northern Israel, and from 1999 all the samples were tested also for Hgb S, Hgb C, Hgb D, Hgb O Arab and others. In this study, the investigators intend to summarize the results of this preventive program aiming to detect couples at risk for having offspring with Thalassemia or SCA, the compliance regard to genetic counseling and prenatal diagnosis and the incidence of new affected babies born.

Official Title
-----------------
Summary of the Data From the Prevention Programme for Hemoglobinopathies in Northern Israel

Conditions
-----------------
Thalassemia, Sickle Cell Anemia

Intervention / Treatment
-----------------
* Other: Observational


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All pregnant women tested and their husband in those cases that the woman test revealed abnormal hemoglobin. Exclusion Criteria: No exclusion criteria.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| A<br>Thalassemia Minor carriers | Other: Observational<br>* Summary of data<br>|
| B<br>Sickle cell carriers | Other: Observational<br>* Summary of data<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of carriers detected |  | End of study | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Couples referred for prenatal diagnosis |  | End of study | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Thalassemia, Sickle cell anemia, Carrier detection, Prenatal Diagnosis, Genetic counseling
Costs of Care and Adherence to Treatment for Cystic Fibrosis

Study Overview
=================
Brief Summary
-----------------
Evolution of medical care for patients with cystic fibrosis appeared in recent years: prolongation of life expectancy with consequently increased comorbidities and the use of lung transplantation, systematic neonatal screening of new born since 2002, prescription of expensive new molecules or new presentation. This evolution justifies to realize an update of statistics of costs of care and to assess adherence to treatment

Official Title
-----------------
Costs of Care and Adherence to Treatment for Cystic Fibrosis.

Conditions
-----------------
Cystic Fibrosis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with cystic fibrosis, Followed by one of the cystic fibrosis center of the Rhône-Alpes region (pediatric and adult of Lyon and Grenoble) Affiliated to the general scheme of health insurance, And domiciled in the Rhône-Alpes region. Exclusion Criteria: Transplanted patients

Ages Eligible for Study
-----------------
Maximum Age: 99 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| treatment cost |  | 12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| adherence rate for chronic treatment |  | 12 months |
Blood Collection of Patient Presenting in the ED and Prescribed a BNP

Study Overview
=================
Brief Summary
-----------------
Plasma specimen collected from patients presenting in the Emergency Department (ED) with or without Heart Failure (HF) and prescribed a BNP.

Detailed Description
-----------------
Plasma samples are collected from a minimum of 400 subjects. Specimens are used to confirm the currently accepted BNP cut off as and aid in the diagnosis and assessment of HF. Stored specimens for future use in BNP assay development.

Official Title
-----------------
A Blood Collection From Patients Presenting in the Emergency Department and Prescribed a Brain Natriuretic Peptide (BNP) Laboratory Test

Conditions
-----------------
Heart Failure

Intervention / Treatment
-----------------
* Device: In Vitro diagnostic tests


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Males and females >21 years of age Able to understand and willing to provide informed consent Present in to ED BNP test requested Exclusion Criteria: Males and females< 21 years Unable to provide informed consent Not presenting to ED hemolyzed sample

Ages Eligible for Study
-----------------
Minimum Age: 21 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: In Vitro diagnostic tests|Prospective blood collection|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Measure BNP | 400 subjects | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
ED, BNP